INTRODUCTION {#sec1-1}
============

Atrial fibrillation (AF) is epidemiologically the most common cardiac arrhythmia, and it is responsible for 15-20% of all ischemic strokes and 26% of all embolic events. Thrombophilias represent an evolving story that continues to stir controversy for care providers and patients. The predominant thrombophilic mutations include the factor V Leiden mutation, prothrombin gene mutation G20210A, methylenetetrahydrafolate reductase C667T, and deficiencies of the natural anticoagulants proteins C and S, and antithrombin.\[[@ref1][@ref2][@ref3]\]

CASE REPORT {#sec1-2}
===========

An 84-year-old woman was referred to our institution because of palpitations and dyspnea started 1 week before. In her medical history there were hypertension, dyslipidemia and a previous pulmonary embolism (PE). For this reason she was taking warfarin at time of our evaluation. A nonvalvular atrial fibrillation (AF) with HR 96/m was found. At clinical examination there were signs of heart failure (rales and peripheral edema), functional NYHA class III and high BP (170/110).

Because of a previous pulmonary embolism in her clinical history a trans-esophageal echocardiography (TEE) was performed. TEE revealed a left atrial appendage (LAA) roundish mass, sizing 1.2 × 1.2 cm that seemed a thrombus \[[Figure 1](#F1){ref-type="fig"}\]. Regarding echocardiographic features, the mass was hyperechogenic and calcified, suggesting it was an old formation, consistent with an organized thrombus. Dense left atrial spontaneous echo-contrast (SEC) was found. Left atrium was dilated and LVEF% was normal.\[[@ref4]\] International normalized ratio (INR) at presentation was 1.95.

![TEE image of the LAA thrombus at time of first evaluation](JCE-24-64-g001){#F1}

Together with heart failure treatment, intravenous anticoagulation with unfractionated heparin was initiated. The value of aPTT during treatment was 1.9 times. Treatment was complicated by an additional right lower limb embolic event treated by Fogarty arterial embolectomy catheter. In addition, after 7 days of therapy, the LAA thrombus remained unchanged \[[Figure 2](#F2){ref-type="fig"}\].

![TEE image of the LAA thrombus after 7 days of treatment with intravenous unfractionated heparin](JCE-24-64-g002){#F2}

A previous testing revealed heterozygosity for both the factor V Leiden and the methylenetetrahydrofolate reductase C677T mutations inducing resistance activated protein C. The test was performed 5 years before and after PE event. The combination of these thrombophilic factors can probably explain the poor anticoagulant response, additional embolic events and the failure of resolution of the LAA thrombus.\[[@ref5]\] Patient refused transcatheter closure of the LAA and was chronically treated with Novel Oral AntiCoagulant (NOAC), specifically with rivaroxaban, 20 mg OD.

DISCUSSION {#sec1-3}
==========

AF is epidemiologically the most common cardiac arrhythmia, and it is responsible for 15% to 20% of all ischemic strokes and 26% of all embolic events.\[[@ref1][@ref6]\] It is assumed that \>90% of clinically apparent embolisms in AF originate from the LAA.

The case-study emphasizes the importance of the high risk of thrombo-embolism with inherited thrombophilic factors.\[[@ref7][@ref8]\] Besides this thrombophilic status may lead to a resistance to anticoagulation treatment.

For patients with resistance to chronic oral anticoagulation, new therapeutic approaches have been developed. Transcatheter closure of the left atrial appendage (LAA) is becoming more common as an interventional therapy to prevent thromboembolic complications in patients with atrial fibrillation (AF) and contraindications or resistance to chronic oral anticoagulation.\[[@ref6]\]
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